Genmab — Marts 2018
-
good morning. the setup for this
Smoldering ASCENT study is changed to a singel group/ single arm and to measure Stringent complete response rate https://clinicaltrials.gov/archive/NCT03289299/2018_03_01/changes -
I guess that they have learned from Maria-Victoria Mateos' study that asct after all is a too rough treatment in the smoldering setting. http://www.ascopost.com/issues/january-25-2018/carfilzomib-based-treatment-and-transplant-in-smoldering-myeloma/
-
God morgen.
-
God morgen
-
Subcutaneous Daratumumab Potential Game Changer for Multiple Myeloma
Oncology Times: Feb 20, 2018 - https://journals.lww.com/oncology-times/Fulltext/2018/02200/Subcutaneous_Daratumumab_Potential_Game_Changer.18.aspx -
nice words: “This would be extremely practice-changing. Daratumumab has moved from monotherapy in advanced disease to first relapse. And now—at this year's ASH—we have newly diagnosed. That's a lot of dara[tumumab] being used globally. And to be giving a more convenient, potentially safer form of administration is really going to be very practice-changing.”
-
https://www.ncbi.nlm.nih.gov/pubmed/29500635?dopt=Abstract&utm_source=dlvr.it&utm_medium=twitter - Daratumumab augments alloreactive natural killer cell cytotoxicity towards CD38+ multiple myeloma cell lines in a biochemical context mimicking tumour microenvironment conditions. Don't try to read this before you had your coffee....
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind